

# **Sodium valproate versus levotiracetam in migraine prophylaxis: a double-blind randomized clinical trial**

## **Abstract:**

**Background and Objective:** Sodium valproate is an anti-seizure and stabilizing agent used for prophylactic use of migraine headaches. Despite the efficacy of this drug due to complications that cause some patients to not tolerate the drug. The purpose of this study was to compare the efficacy of levothyramine as a less complicated drug and sodium valproate in migraine prophylaxis.

**Methods:** This study was performed in a clinical trials study. 100 migraineurs who referred to the Alavi neurology clinic and indicated the onset of prophylaxis of migraine were studied in two groups of 50, one of which was a group of levetiracetam and another group of sodium valproate Received. Patients received daily 500 mg of drug for 3 months and the effect of the drug on the number of attacks, severity of attacks, and MIDAS score was measured. In all studies, P value was less than 0.05.

**Results:** In both cases, significant improvement was observed in the number of attacks, severity and MIDAS score. In all of the criteria, levetiracetam and sodium valproate were almost identical, except for reducing the number of headache attacks that had a significantly better effect on the levothyramine acetate group ( $P = 0.0001$ )

**Conclusion:** Our study showed that levothyramine acetamin can be used as a good alternative in those who do not tolerate sodium valproate.

**Keywords:** Levetiracetam, Sodium Valproate, Migraine